Cardiovascular complications in long-term survivors after allogeneic hematopoietic stem cell transplantation

Seminars in Hematology

Volumn 49, Issue 1, 2012, Pages 25-34

  Rovó, Alicia ^a   Tichelli, André ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; PYRROLE; RAPAMYCIN; ROSUVASTATIN; VERAPAMIL;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ATHEROSCLEROSIS; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG MEGADOSE; DYSLIPIDEMIA; ENDOTHELIUM INJURY; FAMILY HISTORY; GONAD DYSFUNCTION; GRAFT VERSUS HOST REACTION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOMAGNESEMIA; INCIDENCE; INSULIN SENSITIVITY; INTERVENTION STUDY; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIFESTYLE; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; LONG TERM SURVIVAL; MUSCLE DISEASE; MUSCLE INJURY; MYALGIA; MYOPATHY; OBESITY; PATIENT COUNSELING; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK FACTOR; SCREENING TEST; SODIUM RESTRICTION; WEIGHT CONTROL;

CARDIOVASCULAR DISEASES; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RISK FACTORS; SURVIVORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855387136     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.10.001     Document Type: Article

References (54)

1. Armenian S.H., Bhatia S. Cardiovascular disease after hematopoietic cell transplantation-lessons learned. Haematologica 2008, 93:1132-1136.
2. Tichelli A., Bhatia S., Socie G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol 2008, 142:11-26.
3. Tichelli A., Bucher C., Rovo A., et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 2007, 110:3463-3471.
4. Tichelli A., Passweg J., Wojcik D., et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2008, 93:1203-1210.
5. Chow E.J., Mueller B.A., Baker K.S., et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med 2011, 155:21-32.
6. Armenian S.H., Sun C.L., Mills G., et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:1138-1144.
7. Sun C.L., Francisco L., Kawashima T., et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood 2010, 116:3129-3139.
8. Baker J.E., Fish B.L., Su J., et al. 10 Gy total body irradiation increases risk of coronary sclerosis, degeneration of heart structure and function in a rat model. Int J Radiat Biol 2009, 85:1089-1100.
9. Kuhar M.B. Update on managing hypercholesterolemia. The new NCEP guidelines. AAOHN J 2002, 50:360-364.
10. Majhail N.S., Flowers M.E., Ness K.K., et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2009, 43:49-54.
11. Rovo A., Daikeler T., Halter J., et al. Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor. Haematologica 2011, 96:150-155.
12. Griffith M.L., Savani B.N., Boord J.B. Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood 2010, 116:1197-1204.
13. Taskinen M., Saarinen-Pihkala U.M., Hovi L., Lipsanen-Nyman M. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 2000, 356:993-997.
14. Adams M.J., Lipsitz S.R., Colan S.D., et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004, 22:3139-3148.
15. Aleman B.M.P., van den Belt-Dusebout A., De Bruin M.L., et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007, 109:1878-1886.
16. Bouillon K., Haddy N., Delaloge S., et al. Long-term cardiovascular mortality after radiotherapy for breast cancer. J Am Coll Cardiol 2011, 57:445-452.
17. Nilsson G., Holmberg L., Garmo H., Terent A., Blomqvist C. Increased incidence of stroke in women with breast cancer. Eur J Cancer 2005, 41:423-429.
18. Dorresteijn L.D., Kappelle A.C., Boogerd W., et al. Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol 2002, 20:282-288.
19. Smith G.L., Smith B.D., Buchholz T.A., et al. Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol 2008, 26:5119-5125.
20. Murray R.D., Shalet S.M. Insulin sensitivity is impaired in adults with varying degrees of GH deficiency. Clin Endocrinol (Oxf) 2005, 62:182-188.
21. Taskinen M., Lipsanen-Nyman M., Tiitinen A., Hovi L., Saarinen-Pihkala U.M. Insufficient growth hormone secretion is associated with metabolic syndrome after allogeneic stem cell transplantation in childhood. J Pediatr Hematol Oncol 2007, 29:529-534.
22. Nuver J., Smit A.J., Postma A., Sleijfer D.T., Gietema J.A. The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures. Cancer Treat Rev 2002, 28:195-214.
23. Steffens M., Beauloye V., Brichard B., et al. Endocrine and metabolic disorders in young adult survivors of childhood acute lymphoblastic leukaemia (ALL) or non-Hodgkin lymphoma (NHL). Clin Endocrinol (Oxf) 2008, 69:819-827.
24. Singh S.K., Goyal R., Pratyush D.D. Is hypoandrogenemia a component of metabolic syndrome in males?. Exp Clin Endocrinol Diabetes 2011, 119:30-35.
25. Rutter M.M., Rose S.R. Long-term endocrine sequelae of childhood cancer. Curr Opin Pediatr 2007, 19:480-487.
26. Airaghi L., Usardi P., Forti S., et al. A comparison between metabolic syndrome post-hematopoietic stem cell transplantation and spontaneously occurring metabolic syndrome. J Endocrinol Invest 2011, 34:e6-e11.
27. Annaloro C., Usardi P., Airaghi L., et al. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 41:797-804.
28. Champagne C.M. Magnesium in hypertension, cardiovascular disease, metabolic syndrome, and other conditions: a review. Nutr Clin Pract 2008, 23:142-151.
29. Chaudhary D.P., Sharma R., Bansal D.D. Implications of magnesium deficiency in type 2 diabetes: a review. Biol Trace Elem Res 2010, 134:119-129.
30. Aisa Y., Mori T., Nakazato T., et al. Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. Transplantation 2005, 80:1046-1050.
31. Soucy K.G., Attarzadeh D.O., Ramachandran R., et al. Single exposure to radiation produces early anti-angiogenic effects in mouse aorta. Radiat Environ Biophys 2010, 49:397-404.
32. Biedermann B.C., Sahner S., Gregor M., et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002, 359:2078-2083.
33. Hausermann P., Walter R.B., Halter J., et al. Cutaneous graft-versus-host disease: a guide for the dermatologist. Dermatology 2008, 216:287-304.
34. Rizzo J.D., Wingard J.R., Tichelli A., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant 2006, 37:249-261.
35. Carter B.L. Implementing the new guidelines for hypertension: JNC 7, ADA, WHO-ISH. J Manag Care Pharm 2004, 10:S18-S25.
36. Cooper D.S., Halpern R., Wood L.C., Levin A.A., Ridgway E.C. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann Intern Med 1984, 101:18-24.
37. Iqbal A., Jorde R., Figenschau Y. Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromso Study. J Intern Med 2006, 260:53-61.
38. Meier C., Staub J.J., Roth C.B., et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001, 86:4860-4866.
39. Heckbert S.R., Kaplan R.C., Weiss N.S., et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001, 161:1709-1713.
40. Meriggiola M.C., Marcovina S., Paulsen C.A., Bremner W.J. Testosterone enanthate at a dose of 200 mg/week decreases HDL-cholesterol levels in healthy men. Int J Androl 1995, 18:237-242.
41. Ginzburg E., Klimas N., Parvus C., et al. Long-term safety of testosterone and growth hormone supplementation: a retrospective study of metabolic, cardiovascular, and oncologic outcomes. J Clin Med Res 2010, 2:159-166.
42. Traish A.M., Guay A., Feeley R., Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009, 30:10-22.
43. Basu R., Dalla M.C., Campioni M., et al. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care 2007, 30:1972-1978.
44. Chrisoulidou A., Beshyah S.A., Rutherford O., et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 2000, 85:3762-3769.
45. Florakis D., Hung V., Kaltsas G., et al. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clin Endocrinol (Oxf) 2000, 53:453-459.
46. Monson J.P., Jonsson P., Koltowska-Haggstrom M., Kourides I. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. Clin Endocrinol (Oxf) 2007, 67:623-628.
47. Savani B.N., Griffith M.L., Jagasia S., Lee S.J. How I treat late effects in adults after allogeneic stem cell transplantation. Blood 2011, 117:3002-3009.
48. Neuvonen P.J., Niemi M., Backman J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006, 80:565-581.
49. Bruckert E., Hayem G., Dejager S., Yau C., Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403-414.
50. Keogh A., Macdonald P., Kaan A., Aboyoun C., Spratt P., Mundy J. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000, 19:529-537.
51. Schrama Y.C., Hene R.J., de Jonge N., et al. Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients: an exercise provocation test. Transplantation 1998, 66:1175-1181.
52. Aliabadi A.Z., Mahr S., Dunkler D., et al. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. Transplantation 2008, 86:1771-1776.
53. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
54. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.